Working… Menu

Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01820832
Recruitment Status : Unknown
Verified March 2013 by Jing Chen, Huashan Hospital.
Recruitment status was:  Not yet recruiting
First Posted : March 29, 2013
Last Update Posted : March 29, 2013
Information provided by (Responsible Party):
Jing Chen, Huashan Hospital

Brief Summary:
The safety and efficacy of Caltriol on mild proteinuria (<1.0g/d) reduction in CKD patients.

Condition or disease Intervention/treatment Phase
Chronic Kidney Disease Proteinuria Drug: Calcitriol Phase 4

Detailed Description:
Proteinuria is not only a capital sign of kidney disease, but also a marker of chronic kidney disease (CKD) progression. Emerging evidence in patients with CKD show that vitamin D and its analogs can reduce proteinuria or albuminuria in the presence of angiotensin-converting enzyme inhibithion. While some of the studies reported that vitamin D receptor activation has been associated with increased serum creatinine and reduced estimated glomerular filtration rates. Therefore, the investigators plan to conduct a randomized clinical study to evaluate the efficacy and safety of Calcitriol in the treatment of mild proteinuria (<1.0g/d) CKD patients,which has no specific treatment at present.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 4 Study of Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD
Study Start Date : March 2013
Estimated Primary Completion Date : December 2014
Estimated Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Calcitriol

Arm Intervention/treatment
Experimental: Calcitriol
General treatments (such as blood pressure control, lipid lowering, and so on) plus Calcitriol 0.5 ug/BIW for 24 weeks.
Drug: Calcitriol
Calcitriol 0.5 ug/BIW for 24 weeks.
Other Name: 1, 25 - dihydroxy Cholecalciferol

No Intervention: Control
General treatments.

Primary Outcome Measures :
  1. the percentage change of proteinuia [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. the proportion of patients achieving at least a 15% decrease in proteinuria [ Time Frame: 24 weeks ]

Other Outcome Measures:
  1. mean change of renal function (serum creatine, cystatin C, eGFR) [ Time Frame: 24 weeks ]
  2. blood pressure [ Time Frame: 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • aged 18-75 years
  • clinical diagnosed and/or biopsy-confirmed primary glomerulonephritis
  • proteinuria 0.15-1.0 g/d in 2 consecutive samples within 4 weeks despite ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) treatment for at least 1 year or ACEI/ARB withdrawal because of of drug intolerances (low blood pressure, cough, hyperkalemia) for at least 1 month
  • estimated glomerular filtration rate (eGFR)>60ml/min/1/73m2
  • corticosteroid and immunosuppressive agents withdrawal for at least 6 months
  • normal blood pressure
  • serum intact parathyroid hormone (iPTH) level >20pg/mL
  • corrected serum calcium level < or = 2.55 mmol/L
  • serum phosphorus level < or = 1.68 mmol/L
  • 24 hours urinary calcium excretion level < or = 7.5 mmol
  • not receive treatment of vitamin D or its analogue within 6 months
  • willigness to give written consent and comply with the study protocol

Exclusion Criteria:

  • history of sensitivity or allergy to calcitriol or other vitamin D analogs
  • pregnancy, lactating women
  • history of severe coexisting disease such as, but not limited to, chronic liver disease, myocardial infarction, cerebrovascular accident, malignant hypertension
  • history of malignancy
  • history of extraskeletal calcification, hyperuricemia, gout, kidney stone, gall stone, bone diseases
  • patients receiving drugs contains of calcium
  • patients receiving cimetidine, trimethoprim, or other drugs which can increase tubular creatinine reabsorption
  • participation in any other trials within 1 month
  • history of non-compliance

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01820832

Layout table for location contacts
Contact: Jing Chen, M.D. PhD 86-21-52889387
Contact: Li You, M.D. PhD 86-21-52888133

Layout table for location information
China, Shanghai
Huashan Hospital, Fudan University Not yet recruiting
Shanghai, Shanghai, China, 200040
Contact: Li You, M.D. PhD    86-21-52888133   
Sponsors and Collaborators
Huashan Hospital
Layout table for investigator information
Principal Investigator: Jing Chen, M.D. PhD Division of Nephrology, Huashan Hospital, Fudan University

Layout table for additonal information
Responsible Party: Jing Chen, Professor, PhD., MD, Renal Division, Huashan Hospital Identifier: NCT01820832     History of Changes
Other Study ID Numbers: Calcitriol-MP-1
First Posted: March 29, 2013    Key Record Dates
Last Update Posted: March 29, 2013
Last Verified: March 2013
Keywords provided by Jing Chen, Huashan Hospital:
mild proteinuria
renal function
blood pressure
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency
Urination Disorders
Urological Manifestations
Signs and Symptoms
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Growth Substances
Bone Density Conservation Agents
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents